an update on cartitude-2: cilta-cel in patients with multiple myeloma in second line
Published 2 years ago • 93 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
2:33
latest results from the cartitude-2 trial of cilta-cel in progressive multiple myeloma
-
2:01
an update on cohort c from the cartitude-2 trial
-
4:40
cartitude-2 trial update and management of neurotoxicities
-
5:05
patient-reported outcomes in cartitude-4: cilta-cel vs soc in r/r multiple myeloma
-
2:32
final results of cartitude-1: cilta-cel in heavily pretreated patients with r/r multiple myeloma
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
10:49
mayo clinic rochester
-
4:04
the future of myeloma treatment and the possibility of cure
-
1:26
insight-mm study update: treatment patterns in first and second-line multiple myeloma
-
3:54
cilta-cel as a potential new soc for r/r multiple myeloma: insights from the cartitude-4 trial
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
2:28
results from the cartitude-2 trial
-
2:31
cilta-cel achieves deep and durable responses for r/r multiple myeloma
-
1:04
the changing role of autosct in the treatment of multiple myeloma in the era of novel agents
-
4:53
cartitude-1: latest data & crs in myeloma treated with cilta-cel
-
1:53
the future of multiple myeloma treatment
-
4:10
update on cartitude-1: car-t in rrmm
-
1:30
cartitude-1: promising initial results of cilta-cel for myeloma
-
1:37
mrd in myeloma
-
1:35
cilta-cel vs ide-cel for r/r multiple myeloma: making the decision in clinical practice
-
0:54
ucartcs1: a novel allogeneic car-t therapy for myeloma